Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Gefitinib

Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment

Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP

Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being

Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.

EGFR Mutation Test

Ki-67 protein expression in tissue will be analysed by IHC method.

Ki-67 protein expression

Karen Atkin

Louis Zhang

Longyun Li

The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.

A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

AstraZeneca

MC MD

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Mitogens

Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.

Wu Yilong

This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	NCT01000740	Non-small Cell ...	EGFR Mutation T... Ki-67 protein e...	-	AstraZeneca
A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology	NCT01106781	Non-Small Cell ...		18 Years -	AstraZeneca
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	NCT01000740	Non-small Cell ...	EGFR Mutation T... Ki-67 protein e...	-	AstraZeneca
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	NCT01000740	Non-small Cell ...	EGFR Mutation T... Ki-67 protein e...	-	AstraZeneca

Spots Global Cancer Trial Database for egfr mutation test